Abstract:Introduction: Despite the development of advanced treatment options, multiple myeloma (MM) remains an incurable disease. Most MM patients ultimately relapse and require further treatments. MM patients who are triple class exposed (TCE) to immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies have particularly poor outcomes and reduced probability to transition to a next therapy option. In the past few years, several novel therapies including Chimeric Antigen Receptor T-cell (CAR-T) therapies and bispecific antibody therapies became available for TCE patients in the later line setting. Using latest data, this study aims to characterize MM patients treated in US Oncology Network, who were TCE with at least 4 prior lines of therapy (4+ prior LOTs), and to describe their characteristics, treatment patterns, and clinical outcomes. Because treatment history such as penta-drug exposure status (at least two PIs, at least two IMiDs, and at least one anti-CD38) and patient characteristics such as race (White and African American) are known to impact disease outcomes, the impact of these subgroups on treatment to discontinuation or death (TTD) and time to next treatment or death (TTNT) were also evaluated. Methods: Patients with MM who were TCE with 4+ prior LOTs were identified retrospectively from the iKnowMed (iKM) oncology EMR database of the US Oncology Network. Those eligible initiated the next line of therapy (index date) from July 3, 2019 (when additional new treatment options became available) through April 3, 2023, and were followed to the earliest of death, last activity, or end of the study period. Clinical outcomes including TTD and TTNT were analyzed and estimated using the Kaplan-Meier method. Results: A total of 561 TCE patients with 4+ prior LOTs were included in the study, including 95 (16.9%) African American, 387 (69.0%) White, and 310 (55.3%) patients who were penta-drug exposed before index. Key demographic and clinical characteristics are listed in Table 1. The mean (SD) number of prior lines of therapy for the overall TCE & 4+ prior LOTs MM patients before index date was 4.6 (1.2). Prior to the index date, most patients were exposed to daratumumab (99.8%), lenalidomide (95.4%), bortezomib (93.2%), pomalidomide (77.7%), and carfilzomib (61.9%). Excluding corticosteroids, the most common index treatments were pomalidomide- (34.4%), daratumumab- (32.2%), and carfilzomib- (29.1%) based regimens. The most frequently used therapy were triplets (55.1%), followed by doublets (29.3%) and quadruplets (11.9%). CAR-T therapies were not captured in the data, and only 3 patients received bispecific antibody therapy. The estimated median (95% CI) TTD and TTNT in months for the overall TCE with 4+ prior LOTs MM patients were 4.2 (3.9, 5.1) and 6.5 (5.5, 7.4), respectively. TTD and TTNT estimates for the three subgroups are listed in Table 2. Conclusions: This study demonstrates there are limited effective treatment options for heavily treated MM patients in the US Oncology Network. Novel therapies have not been widely used. Clinical outcomes in these patients remain poor, as demonstrated by the short TTD and TTNT. More than half of the patients in the study were penta-drug exposed, a subgroup that showed even worse clinical outcomes than the overall patient group. Racial disparity was also observed, with African American patients appearing to have shorter TTD and TTNT than White patients. The findings highlight the continued need for effective treatments for heavily treated MM patients, including those with demonstrated particularly poor outcomes. Studies investigating innovative therapies to improve the outcomes for these patients are in process.

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma

Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions

Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers

Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma

A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma

Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model

S183: Novel Combination Immunotherapy For The Treatment Of Relapsed/Refractory Multiple Myeloma: Updated Phase 1B Results For Talquetamab (A Gprc5D X Cd3 Bispecific Antibody) In Combination With Daratumumab

Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Real-World Clinical Outcomes Among Triple-Class Exposed Multiple Myeloma Patients and Subgroups in the US Oncology Network

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data

Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma